Literature DB >> 10744312

High-performance affinity chromatography and immobilized serum albumin as probes for drug- and hormone-protein binding.

D S Hage1, J Austin.   

Abstract

The binding of drugs and hormones to proteins within the blood is an important process in determining the transport, excretion, metabolism and activity of such agents. This paper discusses the combined use of immobilized serum albumin and high-performance affinity chromatography (HPAC) as tools for the study of such binding processes. The general approaches that are used in such work and are illustrated by several examples taken from previous work in the author's laboratory. The type of qualitative and quantitative information that can be obtained by such work is described, including the comparison of relative binding affinities, competitive displacement by other agents or the measurement of equilibrium and rate constants based on immobilized albumin columns. A comparison is also provided between the results that are obtained by these methods and those that are provided by solution-phase albumin. Some newer advances that are highlighted include use of HPAC to examine the binding of non-polar compounds to albumin, the effects of binding site heterogeneity on HPAC measurements and the use of chemically-modified albumin as a tool to examined the site-specific interactions of solutes with albumin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744312     DOI: 10.1016/s0378-4347(99)00445-4

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  17 in total

1.  Development of sulfhydryl-reactive silica for protein immobilization in high-performance affinity chromatography.

Authors:  Rangan Mallik; Chunling Wa; David S Hage
Journal:  Anal Chem       Date:  2007-02-15       Impact factor: 6.986

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

3.  Interpreting physicochemical experimental data sets.

Authors:  Nicola Colclough; Mark C Wenlock
Journal:  J Comput Aided Mol Des       Date:  2015-06-09       Impact factor: 3.686

Review 4.  Analysis of stereoselective drug interactions with serum proteins by high-performance affinity chromatography: A historical perspective.

Authors:  Zhao Li; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2017-01-11       Impact factor: 3.935

5.  Binding of triclosan to human serum albumin: insight into the molecular toxicity of emerging contaminant.

Authors:  Jiabin Chen; Xuefei Zhou; Yalei Zhang; Yanqin Zi; Yajie Qian; Haiping Gao; Shuangshuang Lin
Journal:  Environ Sci Pollut Res Int       Date:  2012-07-21       Impact factor: 4.223

6.  Development of an affinity silica monolith containing alpha1-acid glycoprotein for chiral separations.

Authors:  Rangan Mallik; Hai Xuan; David S Hage
Journal:  J Chromatogr A       Date:  2007-03-25       Impact factor: 4.759

Review 7.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

8.  Development of an affinity silica monolith containing human serum albumin for chiral separations.

Authors:  Rangan Mallik; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2007-03-24       Impact factor: 3.935

9.  Evaluation of indole-based probes for high-throughput screening of drug binding to human serum albumin: Analysis by high-performance affinity chromatography.

Authors:  Mandi L Conrad; Annette C Moser; David S Hage
Journal:  J Sep Sci       Date:  2009-04       Impact factor: 3.645

10.  Studies of verapamil binding to human serum albumin by high-performance affinity chromatography.

Authors:  Rangan Mallik; Michelle J Yoo; Sike Chen; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-10-21       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.